The words of Ándres Manuel López Obrador appear when, according to official figures, El Salvador records: 56,653 cases confirmed by Covid-19 and 1,727 deaths due to this
Mexican President Andrés Manuel López Obrador regretted that Central American countries such as Guatemala, Honduras and El Salvador do not yet have the Covid-19 vaccine.
“It is unfortunate that the countries of Central America are affected, like many other countries in the world, and that they do not have access to the vaccine. That Guatemala Honduras and El Salvador do not have access to the vaccine. How much vaccine is needed to protect these brothers? Well, no, because the population is not large. You must have a vision of solidarity and there must be a universal brotherhood, ”López Obrador stressed during his morning press conferences.
You may be interested in: Government pays $ 12,600 with funds from El Salvador Hospital for publications in international journals
López Obrador’s words appear when, according to official figures, El Salvador records: 56,653 cases confirmed by Covid-19, 1,727 deaths due to this and 3,927 active cases.
In addition, the Mexican president asked the international community to “think about our fellow men” and that this will allow vaccines to reach Central American countries. In the region, only Costa Rica and Panama have already received and applied doses of Pfizer vaccine.
Waiting and no date for the arrival of vaccines
El Salvador is awaiting the arrival of four different types of vaccines for immunization against Covid-19.
At the end of November last year, the government announced that two million doses would come from the pharmaceutical company AstraZeneca, the names of the other three companies were not reported, much less when they arrived in the country.
Read also: The report shows saturation in a hospital in El Salvador
The AstraZeneca and Oxford University vaccine has a lower cost and more favorable storage, transport and logistics conditions compared to other competitors, such as the alliance between the American pharmaceutical company Pfizer and the German BioNTech.
They are much more expensive to manufacture and require refrigeration at low temperatures, which makes their marketing and distribution more difficult, especially in low-income countries around the world.